British politicians plan to grill Pfizer over UK closure
This article was originally published in Scrip
Pfizer's decision to close its R&D facility at Sandwich in Kent in the south-east of England, has prompted members of the UK Parliament's Science and Technology Committee to call on the US company to account for its actions. The committee is contacting Pfizer and David Willetts, the British Minister for Universities and Science, to arrange oral evidence to be heard.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.